Treatment of metastatic solid tumors with SLV-154

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 dose-escalation study evaluates the safety and efficacy of SLV-154 in patients with metastatic solid tumors, including various types of cancer such as squamous cell carcinoma of the head and neck, non-small cell lung cancer, and breast cancer. The study employs a Bayesian optimal interval design to determine the maximum tolerated dose and recommended dosing regimen for SLV-154, which will be administered intravenously in repeated 3-week cycles. The trial aims to assess pharmacokinetics, pharmacodynamics, and immunogenicity, with treatment continuing until disease progression or discontinuation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Men or women (as appropriate for cancer type) of age ≥12 years.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
3. Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
4. Presence of metastatic or recurrent locally advanced cancer.
5. Presence of radiographically measurable disease.
6. Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
10. Adequate hematological profile.
11. Adequate coagulation profile.
12. Adequate hepatic profile.
13. Adequate renal function.
14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
15. For female subjects of childbearing potential, a negative serum pregnancy test.
16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

1. Unstable malignancy involving the central nervous system.
2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
4. Significant cardiovascular event or comorbidity.
5. Significant screening ECG abnormalities.
6. Pregnancy or breastfeeding.
7. Major surgery within 3 weeks before the start of study therapy.
8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
9. Concurrent participation in another therapeutic or imaging clinical trial.
10. Other conditions likely to interfere with a subject's ability to participate in the study.

Where it's running

• Hoag Memorial Hospital Presbyterian
  Newport Beach, California, United States Recruiting
• Washington University
  St Louis, Missouri, United States Recruiting
• Astera Cancer Care
  East Brunswick, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• University Hospitals Cleveland Medical Center
  Cleveland, Ohio, United States Recruiting
• The James Outpatient Care West Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Study coordinator: Hong Ren, MD
• Email: hren@solvetx.com
• Phone: 425-894-2558

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

• Evaluating CJRB-101 with Pembrolizumab for Advanced Cancer

  This study is testing a new treatment combining CJRB-101 with pembrolizumab to see if it helps people with advanced cancers like lung cancer and melanoma feel better and respond better to their treatment.

  Recruiting at 4 sites Phase 1/2 CJ Bioscience, Inc. · Irvine, California and 3 other locations · NCT05877430

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• POLARIS — Ablative radiotherapy with immunotherapy for people with multiple metastatic lesions

  This pilot tests whether giving focused high-dose radiation to up to 10 metastatic tumors while patients are on immunotherapy helps people with advanced solid tumors who have 3–10 metastases.

  Recruiting Phase 1 University of Illinois Chicago · Chicago, Illinois · NCT07269080

• Monthly digital financial hardship screening for people with advanced cancer

  This project tests whether monthly remote digital financial hardship screening helps adults with advanced or metastatic cancer who are receiving non-curative systemic therapy.

  Recruiting at 7 sites Alliance Foundation Trials, LLC. · Phoenix, Arizona and 6 other locations · NCT06963723

• Evaluating ALK202 for advanced solid tumors

  This study is testing a new drug called ALK202 to see if it is safe and effective for adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Shanghai Allink Biotherapeutics Co., Ltd. · Margate, Florida and 3 other locations · NCT06707610

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.